BMY

Healthcare Earnings Update Featuring Johnson and Johnson, Cardinal Health and Abbott Labs

by

The upcoming deluge of earnings over the next couple of weeks offers a glimpse into the ongoing business prospects for the various companies in our coverage universe. Let’s discuss the recent news release of a few prominent names in the healthcare industry. Alexander J. Poulos Is There Trouble Brewing at JNJ? Image Source: Johnson & Johnson Shares of Johnson and Johnson (JNJ) faced modest share-price pressure following its first-quarter earnings results April 18. Though we still like J&J in both newsletter portfolios, we were somewhat concerned about its less-than-stellar showing during the quarter in the all-important Pharmaceutical division, which accounts for over 40% of JNJ’s sales. During the period, revenue still increased in its Pharmaceutical division (+0.8 worldwide; 1.4% operationally) … Read more

Update: Frequently Asked Questions About Valuentum Securities, Inc.

by

What is Valuentum Securities? Valuentum (val∙u∙n∙tum) [val-yoo-en-tuh-m] Securities Inc. is an independent investment research publisher, offering premium equity reports and dividend reports, as well as commentary across all sectors/companies, a Best Ideas Newsletter (spanning market caps, asset classes), a Dividend Growth Newsletter, modeling tools/products, and more. Independence and integrity remain our core, and we strive to be a champion of the investor. Valuentum is based in the Chicagoland area. Valuentum is not a money manager, broker, or financial advisor. Valuentum is a publisher of financial information. How do I subscribe to Valuentum’s investment research services? 1)    Click the following link: signup-page. 2)    Select your membership plan. 3)    Enter your contact details. 4)    Click ‘Sign Up.’ 5)    Complete your purchase. 6)   Your payment profile may be recurring, so please check … Read more

Excited By COVID-19 Vaccine Candidates

by

Image Shown: The race is on to find a cure, or better yet a vaccine, for COVID-19. Image Source: Pfizer Inc – First Quarter 2020 Earnings IR Presentation Key Takeaways The race for a COVID-19 cure and vaccine is rapidly evolving with a lot of exciting press releases being put forth. Gilead has taken the lead with a viable treatment, Sorrento is working toward a cure, and it seems most all of big pharma and biotech is racing to find a vaccine, from Johnson & Johnson to Sanofi/GSK and beyond. Though the evaluation of the full data set from a Phase 2 clinical trial means a lot more than the evaluation of a limited set of data from a Phase … Read more

Dividend Increases/Decreases for the Week of December 9

by

Below we provide a list of firms that raised their dividends during the week ending December 9. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week                Abbott Laboratories (ABT): now $0.51 per share quarterly dividend, was $0.47. ABM Industries (ABM): now $0.22 per share quarterly dividend, was $0.195. AGNC Investment Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (AGNCN): now $0.5743 per share quarterly dividend was $0.4375. Albany (AIN): now $0.25 per share quarterly dividend, was $0.21. Alexandria Real Estate Equities (ARE): now $1.21 per share quarterly dividend, was $1.18. AltaGas … Read more

How the FDA’s Delay of Baricitinib Impacts Eli Lilly and Incyte

by

Image Source: Paul Sableman The FDA dealt Eli Lilly and Incyte an unforeseen blow recently by rejecting their marketing application for Rheumatoid Arthritis candidate Baricitinib. Where does the duo go from here? By Alexander J. Poulos an Kris Rosemann The drug approval process is chock full of pitfalls, and until regulators give the final okay, anything can happen. The widely held consensus was Eli Lilly’s (LLY) and Incyte’s (INCY) marketing application for Rheumatoid Arthritis candidate Baricitinib would be approved, but the FDA shocked everyone by issuing a complete response letter requesting further data. Where does the duo of Eli Lilly and Incyte proceed from here? Baricitinib We were optimistic the FDA would approve Baricitinib for the indication of Rheumatoid Arthritis … Read more

2,350-2,750 on the S&P? Could the Coronavirus Catalyze a Financial Crisis?

by

Image: We think a rather modest sell-off in the market to the target range of 2,350-2,750 on the S&P 500 is rather reasonable in the wake of one of the biggest economic shocks since the Global Financial Crisis. The chart above shows how far markets have advanced since 2011, and an adjustment lower to the target range of 2,350-2,750 is rather modest in such a context and would only bring markets to late 2018 levels (note red box as the target range). The range reflects ~16x S&P 500 12-month forward earnings estimates, as of February 14, adjusted down 10% due to COVID-19. When companies like Visa talk about a couple percentage points taken off of growth rates, one knows that … Read more

Dividend Increases/Decreases for the Week December 11

by

Below we provide a list of firms that raised their dividends during the week ending December 11. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Abbott Laboratories (ABT): now $0.45 per share quarterly dividend, was $0.36. Abitibi Royalties (ATBYF): now CAD 0.015 per share monthly dividend, was CAD 0.013. AES (AES): now $0.1505 per share quarterly dividend, was $0.1433. Albany (AIN): now $0.20 per share quarterly dividend, was $0.19. Alexandria Real Estate Equities (ARE): now $1.09 per share quarterly dividend, was $1.06. Alico (ALCO): now $0.18 per share quarterly dividend, was … Read more

Earnings Update on European Big Pharma Featuring Novartis, Sanofi, and AstraZeneca

by

The drug industry is a global market with an impressive array of competitors headquartered outside the US. The quest to bring forth novel treatments continues. We continue to focus on the large-cap traditional pharmaceutical companies for their defensive characteristics, and many also pay a generous dividend. By Alexander J. Poulos Novartis Poised to Cycle Through Loss of Patent Exclusivity on Gleevec Shares of European heavyweight Novartis (NVS) jumped sharply after posting first-quarter earnings April 25. Growth in the pharmaceutical segment remains hampered as the company lapses the loss of patent exclusivity of one of its top-selling products Gleevec. We are looking past the patent cliff and remain focused on the growth products currently in Novartis’ lineup. Cosentyx, a treatment for … Read more